Format

Send to

Choose Destination
Annu Rev Pathol. 2017 Jan 24;12:305-330. doi: 10.1146/annurev-pathol-052016-100304. Epub 2016 Dec 5.

Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.

Author information

1
Department of Laboratory Medicine, University of California, San Francisco, California 94143; email: Jonathan.Esensten@ucsf.edu.
2
Diabetes Center and Department of Medicine, University of California, San Francisco, California 94143; email: Jeff.Bluestone@ucsf.edu.
3
Department of Cellular and Molecular Pharmacology, University of California, San Francisco 94158-2517; email: Wendell.Lim@ucsf.edu.

Abstract

Engineered T cells are currently in clinical trials to treat patients with cancer, solid organ transplants, and autoimmune diseases. However, the field is still in its infancy. The design, and manufacturing, of T cell therapies is not standardized and is performed mostly in academic settings by competing groups. Reliable methods to define dose and pharmacokinetics of T cell therapies need to be developed. As of mid-2016, there are no US Food and Drug Administration (FDA)-approved T cell therapeutics on the market, and FDA regulations are only slowly adapting to the new technologies. Further development of engineered T cell therapies requires advances in immunology, synthetic biology, manufacturing processes, and government regulation. In this review, we outline some of these challenges and discuss the contributions that pathologists can make to this emerging field.

KEYWORDS:

T cells; cellular engineering; cellular therapy; immunotherapy; synthetic biology

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center